Form 4: Dexcom EVP Jacob Steven Leach Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Executive Vice President and Chief Operating Officer of Dexcom, Jacob Steven Leach, reports selling shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Jacob Steven Leach, EVP and Chief Operating Officer of Dexcom, filed a Form 4.
- On March 12, 2025, Leach sold 14,076 shares of Dexcom common stock at a price of $70.3801 per share.
- The sale was mandated by Dexcom's equity incentive plans to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
- Following the transaction, Leach directly owns 313,497 shares of Dexcom, which includes 84,537 unvested restricted stock units.
- Leach also indirectly owns 47,296 shares through Family Holdings.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies. It provides transparency into executive stock ownership and transactions.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across the industry, including companies like Medtronic, Abbott, and Boston Scientific.
- The amount of shares sold is proportional to the executive's compensation package and the company's stock price performance, aligning with industry norms.
Stakeholder Impact
- The stock sale has a minimal impact on shareholders as it is a routine transaction to cover tax obligations.
- The transaction does not directly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/30/2010 | Date of Gregg Family Grandchildren's Trust UAD |
| 03/08/2023 | Grant date of 8,465 unvested restricted stock units which shall vest through March 8, 2026 |
| 03/08/2024 | Grant date of 17,368 unvested restricted stock units which shall vest through March 8, 2027 |
| 03/08/2025 | Grant date of 35,906 unvested restricted stock units which shall vest through March 8, 2028 |
| 03/08/2025 | Grant date of 22,798 unvested restricted stock units which shall vest through March 8, 2027 |
| 03/12/2025 | Date of stock sale transaction |
| 03/14/2025 | Date of Form 4 filing |
| 03/08/2026 | Vesting date of 8,465 unvested restricted stock units granted on March 8, 2023 |
| 03/08/2027 | Vesting date of 17,368 unvested restricted stock units granted on March 8, 2024 |
| 03/08/2027 | Vesting date of 22,798 unvested restricted stock units granted on March 8, 2025 |
| 03/08/2028 | Vesting date of 35,906 unvested restricted stock units granted on March 8, 2025 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.